Market Overview

Benzinga's Top Pre-Market Gainers

Related GNOM
Benzinga Market Primer: Wednesday, March 13
BGI-Shenzhen Receives Approval from Ministry of Commerce of PRC for Proposed Acquisition Of Complete Genomics
Related MRK
KEYTRUDA® (pembrolizumab) Receives New Draft Recommendation from National Institute for Health and Care Excellence (NICE) in U.K. for First-Line Treatment for Advanced Melanoma
Agilent Company Dako, Announces FDA Approval of New Companion Diagnostic for Lung Cancer
Bristol-Myers drug approved (Investor's Business Daily)

Complete Genomics (NASDAQ: GNOM) surged 9.22% to $3.20 in the pre-market session. Complete Genomics announced new technology developed for clinical-grade genomes.

Merck & Co (NYSE: MRK) added 3.98% to $42.85 in the pre-market session. Analysts at Citigroup upgraded Merck from “neutral” to “buy.”

SunPower (NASDAQ: SPWR) moved up 1.52% to $4.67 in the pre-market session. Analysts at Piper Jaffray upgraded SunPower from “neutral” to “overweight.”

Ocean Power Technologies (NASDAQ: OPTT) soared 1.41% to $3.60 in the pre-market trading. Ocean Power Technologies and Lockheed Martin (NYSE: LMT) have entered into a teaming agreement to develop a 19 megawatt wave-energy project in Victoria, Australia.

Posted-In: Top Pre-Market GainersNews Pre-Market Outlook Markets Movers


Related Articles (LMT + GNOM)

Get Benzinga's Newsletters